IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of Buy from Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) have been given an average rating of “Buy” by the eleven analysts that are covering the company, MarketBeat reports. Eleven investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have covered the stock in the […]

Related Keywords

Switzerland ,Canada ,Swiss ,Yujiros Hata , ,Nasdaq ,Biosciences Inc ,Metlife Investment Management ,Goldman Sachs Group ,Biosciences Company Profile ,Swiss National Bank ,Royal Bank ,Jpmorgan Chase Co ,Dimensional Fund Advisors ,Get Free Report ,Jason Throne ,National Bank ,Life Investment Management ,Fund Advisors ,Get Free ,Ideaya Biosciences ,Nasdaq Idya ,Nidya ,Medical ,Ratings ,Consensus ,